News | Neuro Imaging | June 30, 2016

MRI study reveals increased response in key brain areas, suggesting potential treatment for a variety of cognitive impairments

methylene blue, short-term memory, MRI study, University of Texas Health Science Center, Timothy Q. Duong

June 30, 2016 — A single oral dose of methylene blue results in an increased magnetic resonance imaging (MRI)-based response in brain areas that control short-term memory and attention, according to a new study published online in the journal Radiology.

Methylene blue is used to treat methemoglobinemia, a blood disorder in which oxygen is unable to release effectively to body tissues, and as a surgical stain.

Animal studies have shown a single low dose of methylene blue enhances long-term contextual memory — the conscious recall of the source and circumstances of a specific memory — and extinction memory, a process in which a conditioned response from stimuli gradually diminishes over time.

“Although the memory-enhancing effects of methylene blue were shown in rodents in the 1970s, the underlying neuronal changes in the brain responsible for memory improvement and the effects of methylene blue on short-term memory and sustained-attention tasks have not been investigated,” said study author Timothy Q. Duong, Ph.D., from the University of Texas Health Science Center at San Antonio, Texas. “Our team decided to conduct the first multi-modal MRI study of methylene blue in humans.”

Twenty-six healthy participants, between the ages of 22 and 62, were enrolled in a double-blinded, randomized, placebo-controlled clinical trial to measure the effects of methylene blue on the human brain during working-memory and sustained-attention tasks. This study was approved by the local ethical committee.

The participants underwent functional MRI (fMRI) before and one hour after low-dose methylene blue or placebo administration to evaluate the potential effects of methylene blue on cerebrovascular reactivity during tasks. Mean cerebral blood flow was measured pre- and post-intervention.

The results showed methylene blue increased response in the bilateral insular cortex — an area deep within the brain associated with emotional responses — during a task that measured reaction time to a visual stimulus. The fMRI results also showed an increased response during short-term memory tasks involving the brain’s prefrontal cortex (which controls processing of memories, the parietal lobe (primarily associated with the processing of sensory information) and the occipital cortex (the visual processing center of the brain). In addition, methylene blue was associated with a 7 percent increase in correct responses during memory retrieval.

The findings suggest that methylene blue can regulate certain brain networks related to sustained attention and short-term memory after a single oral low dose.

“This work certainly provides a foundation for future trials of methylene blue in healthy aging, cognitive impairment, dementia and other conditions that might benefit from drug-induced memory enhancement,” Duong said.

For more information: www.pubs.rsna.org/journal/radiology


Related Content

News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | HIMSS

March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) ...

Time March 03, 2026
arrow
News

Feb. 26, 2026 — GE HealthCare and UCSF Health have announced a 10-year Care Alliance collaboration focused on ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | PET Imaging

Feb. 19, 2026 — Positrigo, a Swiss based company developing nuclear medical devices to advance functional brain imaging ...

Time February 26, 2026
arrow
News | Contrast Media

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

Time February 24, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | ARRS

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Time February 13, 2026
arrow
Subscribe Now